News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Protolabs (PRLB) CEO and President Suresh Krishna joins Market Domination's Josh Lipton to discuss the Trump administration considering additional semiconductor tariffs and the American reshoring of manufacturing.
Merit Medical's 22.2% monthly rally gains support from stronger Q2 growth and a raised 2026 outlook, but valuation and tariff risks remain.
TCW Funds, an investment management firm, published its second-quarter 2026 investor letter for the ‘TCW Concentrated Large Cap Growth Fund.’ A copy of the letter can be downloaded here. During the second quarter, AI monetization, a fragile Middle East ceasefire, and a Federal Reserve leadership transition were the significant events. All major indices ended higher, […]
AngioDynamics' Med Tech growth and reimbursement gains strengthen its outlook, but tariffs, rising costs and execution risks keep the buy case uncertain.
AngioDynamics' fiscal 2027 outlook hinges on Med Tech growth offsetting flat device sales as tariffs, spending and losses pressure margins.
AngioDynamics' 33.5% three-month rally rests on Med Tech growth, but valuation, tariffs and negative earnings keep execution risks high.
Wall Street analysts are busy reshuffling their ratings ahead of the Fed meeting, with surprise double-upgrades, dramatic target cuts, and fresh initiations spanning surgical robots to cybersecurity. Find out which names made the biggest moves today.
The trade tech company says Cervo AI can speed up customs brokerage tasks as tariff and trade policies shift.
Boston Scientific Corporation (NYSE:BSX) was among the stocks Jim Cramer discussed as he said that the Iran peace negotiations could trigger an oil glut, cool inflation, and pull interest rates down. A caller asked about Cramer’s thoughts on the stock, and he replied: Now, I gotta tell you something, I was shocked at the decline […]
TFX targets $2.03B in divestiture proceeds; FTC review, tariffs and remediation costs put 2026 timing, margins and leverage in play.